SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 11/05/08 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive
Officer, is scheduled to present corporate updates at two investor
conferences in November:
Mr. Blum plans to present at Rodman & Renshaw's 10th Annual Healthcare
Conference on Wednesday, November 12, 2008 at 9:30 a.m. Eastern Time at The
Palace Hotel in New York, New York.
He is also scheduled to present at the 17th Annual Credit Suisse Annual
Global Healthcare Conference on Thursday, November 13, 2008 at 10:30 a.m.
Mountain Time at The Arizona Biltmore Hotel in Phoenix, Arizona.
Interested parties may access the live audio webcast of these presentations
and replays by visiting the Investors Relations section of the Cytokinetics
website at www.cytokinetics.com. The webcast replay of the presentation
will be archived on the Presentations page within the Investors Relations
section of Cytokinetics' website for two weeks following the completion of
each of the events.
About Cytokinetics
Cytokinetics is a biopharmaceutical company focused on the discovery,
development and commercialization of novel small molecule drugs that may
address areas of significant unmet clinical needs. Cytokinetics'
cardiovascular disease program is focused to cardiac myosin, a motor
protein essential to cardiac muscle contraction. Cytokinetics' lead
compound from this program, CK-1827452, a novel small molecule cardiac
myosin activator, entered Phase II clinical trials for the treatment of
heart failure in 2007. Under a strategic alliance established in 2006,
Cytokinetics and Amgen Inc. are performing joint research focused on
identifying and characterizing activators of cardiac myosin as back-up and
follow-on potential drug candidates to CK-1827452. Amgen has obtained an
option for an exclusive license to develop and commercialize CK-1827452,
subject to Cytokinetics' development and commercial participation rights.
Cytokinetics' cancer program is focused on mitotic kinesins, a family of
motor proteins essential to cell division. Under a strategic alliance
established in 2001, Cytokinetics and GlaxoSmithKline (GSK) are conducting
research and development activities focused on the potential treatment of
cancer. Cytokinetics is developing two novel drug candidates that have
arisen from this program, ispinesib and SB-743921, each a novel inhibitor
of kinesin spindle protein (KSP), a mitotic kinesin. Cytokinetics is
conducting the Phase I portion of a Phase I/II clinical trial of ispinesib
as monotherapy as a first-line treatment in chemotherapy-naïve patients
with locally advanced or metastatic breast cancer.
